Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 7/20 | 0.45 |
| ▸ | LIPE | Q05469 | 7/20 | 0.41 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.39 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14646795 | 1.00 | BTK (0.45) | BTKLIPENTRK1NTRK2HDAC1 | |
| SCHEMBL27003887 | 0.86 | LIPE (0.39) | BTKLIPENTRK1NTRK2HDAC1 | |
| SCHEMBL27003891 | 0.84 | LIPE (0.39) | LIPENTRK1NTRK2HDAC1NPC1 | |
| SCHEMBL14646759 | 0.82 | LIPE (0.43) | BTKLIPENPC1TP53RAB9A | |
| SCHEMBL31473998 | 0.82 | LIPE (0.36) | BTKLIPENTRK1NTRK2HDAC1 | |
| SCHEMBL27437425 | 0.82 | LIPE (0.37) | BTKLIPENTRK1NTRK2 | |
| SCHEMBL29814325 | 0.82 | LIPE (0.37) | BTKLIPENTRK1NTRK2 | |
| SCHEMBL16754856 | 0.81 | BTK (0.45) | BTK | |
| SCHEMBL29520132 | 0.81 | BTK (0.45) | BTK | |
| SCHEMBL18130791 | 0.81 | LIPE (0.47) | BTKLIPENTRK1NTRK2HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12441733-B2 | Substituted 2,4-dioxotetrahydropyrimidines as intermediates in the synthesis of bruton's tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2025-10-14 | — | — | US | disclosed |
| EP-4304655-A1 | FATTY ACID-BIFUNCTIONAL DEGRADER CONJUGATES AND THEIR METHODS OF USE | Novartis AG (CH) | 2024-01-17 | — | — | EP | disclosed |
| EP-4146655-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BeiGene, Ltd. (KY) | 2023-03-15 | — | — | EP | disclosed |
| WO-2022189859-A1 | FATTY ACID-BIFUNCTIONAL DEGRADER CONJUGATES AND THEIR METHODS OF USE | NOVARTIS AG (CH) | 2022-09-15 | — | — | WO | disclosed |
| EP-4031247-A1 | BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE | Novartis AG (CH) | 2022-07-27 | — | — | EP | disclosed |
| CN-114521196-A | Bifunctional group degradation agent and use method thereof | 诺华股份有限公司 | 2022-05-20 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12441733-B2 | Substituted 2,4-dioxotetrahydropyrimidines as intermediates in the synthesis of bruton's tyrosine kinase inhibitors | BTK, ABL1, LYN | BTK 1/4885LIPE 4698/4885NTRK1 2469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.